Eisai Obtains Cancer Drug Rights From Prism Biolab
This article was originally published in PharmAsia News
Executive Summary
Eisai Co. Ltd. and Yokohama-based Japanese biotech venture firm Prism Biolab announced a license deal for PRI-724, a CBP/beta-catenin inhibitor, and analogous compounds